In this study, we expanded the target population by including patients after treatment and with recurrent bladder cancer to further evaluate the diagnostic performance of VI-RADS. The diagnostic performances of VI-RADS were good in all subgroups including the primary, post-treatment and recurrence groups (AUC > 0.90). No significant differences were observed in diagnostic efficacy of VI-RADS between the primary group and the post-treatment group, and between the primary group and the recurrence group. Overall, this study demonstrated that VI-RADS can be considered an effective preoperative imaging staging tool for a wider range of bladder cancer patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords